The Hetero Ring Is Three-membered Patents (Class 514/475)
  • Patent number: 10265271
    Abstract: The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: April 23, 2019
    Assignee: Biosphere Medical, Inc.
    Inventors: Jean-Marie Vogel, Egisto Boschetti
  • Patent number: 10231946
    Abstract: The invention generally relates to methods of treating a patient suffering from renal disorders or other disorders related to low levels of sRAGE, and/or low levels of adiponectin (e.g., high molecular weight adiponectin) and/or high levels of thrombomodulin, using effective of amounts of a MetAP-2 inhibitor.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: March 19, 2019
    Assignee: Zafgen, Inc.
    Inventors: Thomas E. Hughes, James E. Vath
  • Patent number: 10233452
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: March 19, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., Alnylam Pharmaceuticals, Inc.
    Inventors: William G. Kaelin, Jr., Victor Kotelianski, William Querbes, Brian Bettencourt
  • Patent number: 10149644
    Abstract: The present invention provides curcumin-derived near infrared (NIR) imaging probes. Upon interacting with amyloid ? aggregates, these probes undergo a range of changes, qualifying them as “smart” probes. The inventors have demonstrated that probes of the invention have the capacity to monitor the progression of Alzheimer's disease in an in vivo animal model. In addition, the present invention encompasses probes useful as PET imaging agents, MRI imaging agents and multimodal imaging agents, as well as related methods of detecting and imaging amyloid ? aggregates and plaques.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: December 11, 2018
    Assignee: The General Hospital Corporation
    Inventors: Chongzhao Ran, Anna Moore
  • Patent number: 10010544
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: July 3, 2018
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • Patent number: 9956235
    Abstract: Provided are compositions and methods for reducing the reproductive capacity of mammals. The compositions and methods involve the use and administration of (a) a diterpenoid epoxide comprising a triptolide skeleton and which causes ovarian follicle depletion in female mammals and (b) an organic diepoxide which causes ovarian follicle depletion in female mammals.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: May 1, 2018
    Assignee: SENESTECH, INC.
    Inventors: Lorretta P. Mayer, Cheryl A. Dyer
  • Patent number: 9925166
    Abstract: The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: March 27, 2018
    Assignee: Zafgen, Inc.
    Inventor: James E. Vath
  • Patent number: 9913867
    Abstract: The present invention relates to a composition comprising an extract of a mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis, wherein the composition has the excellent effect of treating atopic dermatitis through the synergistic interaction of the anti-inflammatory effect of Undaria pinnatifida sporophylls and the cell regenerative effect of ascidian shells. The composition of the invention is not involved in the suppression of cytokine production. However, it is assumed that the composition has the effects of suppressing inflammation as well as regenerating skin.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: March 13, 2018
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Beyong-dae Choi, Seong-hun Jeong, Shi-hyang Park, Myung-sook Kim, Soon-ok Choi
  • Patent number: 9895449
    Abstract: One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: February 20, 2018
    Assignee: SynDevRx, Inc.
    Inventor: John S. Petersen
  • Patent number: 9862667
    Abstract: This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: January 9, 2018
    Assignees: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Marianne D. Sadar, Nasrin R. Mawji, Jun Wang, Raymond J. Andersen, David E. Williams, Mike Leblanc
  • Patent number: 9849106
    Abstract: The invention generally relates to methods of treating a patient suffering from renal disorders or other disorders related to low levels of sRAGE, and/or low levels of adiponectin (e.g., high molecular weight adiponectin) and/or high levels of thrombomodulin, using effective of amounts of a MetAP-2 inhibitor.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 26, 2017
    Assignee: Zafgen, Inc.
    Inventors: Thomas E. Hughes, James E. Vath
  • Patent number: 9827214
    Abstract: An oleogel comprising a non-polar liquid and a powder containing triterpene is provided as an oleogel that may be used for healing wounds.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: November 28, 2017
    Assignee: AMRYT RESEARCH LIMITED
    Inventor: Armin Scheffler
  • Patent number: 9827255
    Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof and pharmaceutically acceptable salts of the compounds and stereoisomers, wherein R1 and R2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 28, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Zacharia Cheruvallath, John David Lawson, Christopher McBride
  • Patent number: 9814693
    Abstract: The present invention is directed to methods for treatment of malignancies in companion animals employing dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol, as well as analogs and derivatives thereof, in addition to a method to improve the efficacy and/or reduce the side effects of the administration of a therapeutic agent selected from the group consisting of dianhydrogalactitol, a derivative of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative of dibromodulcitol to a veterinary subject, the method comprising the steps of: (1 (identifying at least one factor or parameter associated with the efficacy and/or occurrence of side effects of the administration of the therapeutic agent to the veterinary subject; and (2) modifying the factor or parameter to improve the efficacy and/or reduce the side effects of the administration of the therapeutic agent to the veterinary subject.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: November 14, 2017
    Assignee: DELMAR PHARMACEUTICALS, INC.
    Inventors: Jeffrey A. Bacha, Dennis M. Brown, William J. Garner
  • Patent number: 9757373
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: September 12, 2017
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • Patent number: 9750737
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: September 5, 2017
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • Patent number: 9707203
    Abstract: A method of killing bacteria. The method includes contacting the bacteria with an effective amount of at least one oxidation product of safranal selected from the group consisting of a compound of formula II, a compound of formula III, and stereoisomers thereof. The oxidation products of safranal of formula II and/or formula III are preferably synthesized by subjecting safranal to oxidation reactions either photochemically with at least one peroxide in the presence of light or thermally with at least one organic peracid.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: July 18, 2017
    Assignee: King Abdulaziz University
    Inventors: Suzan Abdulrahman I. Khayyat, Eman Mahmoud Ibraheem Elgendy
  • Patent number: 9676797
    Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 13, 2017
    Assignee: AbbVie Inc.
    Inventors: Hui-Ju J. Chen, David A. DeGoey, John Hartung, Nathan Ide, Vikram Kalthod, Allan C. Krueger, Yi-Yin Ku, Tongmei Li, John T. Randolph, Rolf Wagner, Jaclyn Chau, Geoff T. Halvorsen, Christopher C. Marvin, Eric Voight
  • Patent number: 9649293
    Abstract: The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 16, 2017
    Assignees: Zafgen, Inc., Vanderbilt University
    Inventors: Thomas E. Hughes, James E. Vath, Alan D. Cherrington
  • Patent number: 9630938
    Abstract: The present invention provides an efficient method of synthesizing and purifying dianhydrohexitols such as dianhydrogalactitol. In general, as applied to dianhydrogalactitol, the method comprises: (1) reacting dulcitol with a concentrated solution of hydrobromic acid at a temperature of about 80° C. to produce dibromogalactitol; (2) reacting the dibromogalactitol with potassium carbonate in t-butanol to produce dianhydrogalactitol; and (3) purifying the dianhydrogalactitol using a slurry of ethyl ether to produce purified dianhydrogalactitol. Another method produces dianhydrogalactitol from dulcitol; this method comprises: (1) reacting dulcitol with a reactant to convert the 1,6-hydroxy groups of dulcitol to an effective leaving group to generate an intermediate; and (2) reacting the intermediate with an inorganic weak base to produce dianhydrogalactitol through an intramolecular SN2 reaction. Other methods for the synthesis of dianhydrogalactitol from dulcitol are described.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 25, 2017
    Assignee: DELMAR PHARMACEUTICALS, INC.
    Inventors: Dennis M. Brown, Mike Tso-Ping Li
  • Patent number: 9433600
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 6, 2016
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • Patent number: 9381169
    Abstract: The present invention relates to pharmaceutical compositions comprising polyfunctional metal phenolates that have biological applications as an anticancer adjuvant, cytoprotective antimetastatic agents and antimutagenic agents when associated with chemotherapy drugs. The present invention further relates to the use of said polyfunctional metal phenolates in the preparation of drugs for the treatment, prophylaxis or prevention of neoplasic diseases in humans and animals.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: July 5, 2016
    Assignees: UNIVERSIDADE BANDEIRANTE DE SÃO PAULO—ACADEMIA PAULISTA ANCHIETA S/C LT, FUNDAÇ ÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO—FAPESP
    Inventors: José Agustin Quincoces Suárez, Durvanei Augusto Maria, Paulo Celso Pardi, Fernanda Faião Flores, Reginaldo Pereira Santos, Daniela Gonçales Rando
  • Patent number: 9365502
    Abstract: The present disclosure is generally directed to neuroactive substituted cyclopenta[b]phenanthrenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: June 14, 2016
    Assignee: WASHINGTON UNIVERSITY
    Inventor: Douglas Covey
  • Patent number: 9333194
    Abstract: The present invention provides novel angiogenesis inhibitors effective, safe and highly practical for inhibition of angiogenesis in various diseases, and a method for screening the same. The active ingredients of the angiogenesis inhibitors of the present invention comprise ansamycin antibiotics such as rifampicin, rifamycin SV and 3-formyl rifamycin, which have long been used extensively as antibacterial agents for treating tuberculosis or Gram-positive bacterial infections. The active ingredients of the present invention have excellent angiogenesis-inhibiting activity. The angiogenesis inhibitor of the present invention is effective for inhibition of angiogenesis in malignant tumors, diabetic retinopathy, retinal angiogenesis, inflammatory diseases, and angiogenesis accompanying cardiovascular remodeling, etc., and can be used as therapeutic agents against each disease, etc.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: May 10, 2016
    Assignee: Japan Science & Technology Agency
    Inventors: Masayoshi Shichiri, Yujiro Tanaka
  • Patent number: 9320805
    Abstract: One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: April 26, 2016
    Assignee: SynDevRx, Inc.
    Inventor: John S. Petersen
  • Patent number: 9315448
    Abstract: The present invention concerns a pharmaceutical composition comprising a compound of formula A being (2,3(dihydroxy), 5[3(1,2)butadiene], 1(3hydroxy,3methyl,4pentene)benzene) and/or a compound of formula B being (2,3(dihydroxy), 5[3(1,2)butadiene], 2[2methylbutane]benzenal) and/or a compound of formula C being (2,3(dihydroxy), 5[3(1,2)butadiene], 2hydroxy,3butene benzoate) or a combination thereof for use as a medicament or for in vivo use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: April 19, 2016
    Assignee: Cesa Alliance S.A.
    Inventors: Christine Coppens, Willem Van Cauter
  • Patent number: 9308169
    Abstract: The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: April 12, 2016
    Assignee: Biosphere Medical, Inc.
    Inventors: Jean-Marie Vogel, Egisto Boschetti
  • Patent number: 9289410
    Abstract: The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: March 22, 2016
    Assignee: QBiotics Limited
    Inventors: Paul Warren Reddell, Victoria Anne Gordon
  • Patent number: 9259411
    Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: February 16, 2016
    Inventors: Peter Andrew Ferchmin, Vesna Ana Eterovic De Ferchmin, Hector Manuel Maldonado, Khalid El Sayed
  • Patent number: 9238634
    Abstract: The purpose is to provide a compound which can overcomes the disadvantages of conventional steroid drugs and NSAID. It is found that specific epoxy monohydroxy forms of eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid which are independently represented by formulae [chemical formula 1], [chemical formula 5] and the like have an inhibitory activity on neutrophils. This compound can inhibit the invasion of neutrophils into tissues and the activation of neutrophils which are observed in acute inflammations.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: January 19, 2016
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Makoto Arita, Hiroyuki Arai, Yosuke Isobe, Tadafumi Kubota
  • Patent number: 9220263
    Abstract: The present invention relates to rodenticides, methods of killing a rodent comprising administering to said rodent, a lethal dose of an isolated Yersinia murine toxin polypeptide or an isolated antigenic analogue thereof, and methods of manufacturing novel rodenticides.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: December 29, 2015
    Assignee: The Secretary of State for Defense
    Inventors: Petra Claire Farquhar Oyston, Graeme Christopher Clark
  • Patent number: 9173956
    Abstract: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: November 3, 2015
    Assignee: SynDevRx, Inc.
    Inventors: John S. Petersen, James Shanahan
  • Patent number: 9173865
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g, a MetAP-2 inhibitor.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: November 3, 2015
    Assignee: Zafgen, Inc.
    Inventor: Thomas E. Hughes
  • Patent number: 9119837
    Abstract: The present invention provides methods and compositions for relieving pain and itching, of promoting wound healing, of reducing sickness behavior and of reducing inflammatory bowel disease or acne lesions in a subject by the topical administration of an inhibitor of soluble epoxide hydrolase, or of a cis-epoxyeicosatrienoic acid (“EET”), or by both.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: September 1, 2015
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Ahmet Bora Inceoglu
  • Patent number: 9089597
    Abstract: Various human diseases, including herpes, antibiotic resistant bacterial infections, cutaneous Leishmaniasis, malaria and multiple sclerosis can be treated with injections of garlic juice. The garlic juice is produced by cutting, crushing, or otherwise damaging garlic cloves, and collecting the juice. This garlic juice is dissolved in a carrier solution, such as water or saline, and then injected into the patient.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: July 28, 2015
    Inventor: Behnam Azizkhani
  • Patent number: 9067913
    Abstract: The disclosure provides a fumagillol type compound and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: June 30, 2015
    Assignee: Zafgen, Inc.
    Inventor: James E. Vath
  • Patent number: 9050284
    Abstract: Disclosed is a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#I. Also disclosed is an anti-acne composition comprising 3,5-dimethoxy-3,4?-dihydroxystilbenes represented by STR#I. Further, a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 2,3?,5?, 6-tetrahydroxy-trans-stilbene represented by STR#II is also disclosed.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: June 9, 2015
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Jeffrey Reinhardt, Kalyanam Nagabhushanam, Samuel Manoharan Thomas, Krishnamani Jayaraman
  • Publication number: 20150148384
    Abstract: Disclosed herein are novel A-ring epoxidized triterpenoid compounds and derivatives thereof, including those of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 28, 2015
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Christopher F. Bender, Xin Jiang, Xiaofeng Liu, Haizhou Sun, Melean Visnick
  • Publication number: 20150126489
    Abstract: The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 7, 2015
    Applicant: ZAFGEN, INC.
    Inventors: Robert Zahler, James E. Vath
  • Publication number: 20150119460
    Abstract: The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.
    Type: Application
    Filed: December 1, 2014
    Publication date: April 30, 2015
    Inventors: Charles N. SERHAN, Rong YANG
  • Publication number: 20150110901
    Abstract: The present invention relates to a novel use of sesquiterpenoid compounds, the pharmaceutically acceptable salts thereof, or the extracts of Cyperus rotundus comprising same or the fractions thereof in the prevention or treatment of menopausal diseases. The sesquiterpenoid compound according to the present invention, the extracts of Cyperus rotundus comprising the same or fractions thereof exhibit excellent estrogenic activity or anti-allergic activity, and therefore they can be used for the prevention or treatment of menopausal diseases caused by a decline in estrogen level or by allergic diseases.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Applicant: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
    Inventors: Kyu Hyuck CHUNG, Jong Hwan KWAK
  • Publication number: 20150111964
    Abstract: The disclosure is in part directed to crystalline forms of an oxalate salt of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 23, 2015
    Applicant: ZAFGEN, INC.
    Inventor: Thomas Crawford
  • Publication number: 20150111963
    Abstract: The disclosure provides a fumagillol type compound and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.
    Type: Application
    Filed: May 22, 2014
    Publication date: April 23, 2015
    Applicant: ZAFGEN, INC.
    Inventor: James E. Vath
  • Patent number: 9006249
    Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: April 14, 2015
    Assignee: Novartis AG
    Inventors: Gary Mark Coppola, Yuki Iwaki, Rajeshri Ganesh Karki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi, Robert Sun
  • Publication number: 20150099803
    Abstract: The present invention is directed to methods for treatment of malignancies in companion animals employing dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol, as well as analogs and derivatives thereof, in addition to a method to improve the efficacy and/or reduce the side effects of the administration of a therapeutic agent selected from the group consisting of dianhydrogalactitol, a derivative of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative of dibromodulcitol to a veterinary subject, the method comprising the steps of: (1 (identifying at least one factor or parameter associated with the efficacy and/or occurrence of side effects of the administration of the therapeutic agent to the veterinary subject; and (2) modifying the factor or parameter to improve the efficacy and/or reduce the side effects of the administration of the therapeutic agent to the veterinary subject.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 9, 2015
    Inventors: Jeffrey A. Bacha, Dennis M. Brown, William A. Garner
  • Patent number: 9000030
    Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: April 7, 2015
    Inventors: Peter Andrew Ferchmin, Vesna Ana Eterovic De Ferchmin, Hector Manuel Maldonado, Khalid El Sayed
  • Patent number: 9000035
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g, a MetAP-2 inhibitor.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: April 7, 2015
    Assignee: Zafgen, Inc.
    Inventor: Thomas E. Hughes
  • Patent number: 8980945
    Abstract: The present invention concerns an antiviral composition comprising the following components: R-(?)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (?) carvone) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (+) carvone) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) in combination with at least one more component chosen among essential oils components for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: March 17, 2015
    Assignee: Cessa Alliance
    Inventor: Christine Coppens
  • Patent number: 8980946
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g., a MetAP-2 inhibitor.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: March 17, 2015
    Assignee: Zafgen, Inc.
    Inventor: Thomas E. Hughes
  • Publication number: 20150065568
    Abstract: A method for producing a composition containing fucoxanthin includes a first step of adding a water-soluble solvent containing 0 to 80% by weight of water to seaweed to obtain a seaweed component extract, and then adding water and/or a water-soluble solvent to the seaweed component extract in such a manner that the concentration of the water-soluble solvent is 20 to 45% by weight and also adding a diluent thereto to obtain a diluent-containing extract, and a second step of stirring the diluent-containing extract, and then collecting a substance aggregating into the diluent-containing extract as a composition containing fucoxanthin by separation.
    Type: Application
    Filed: February 27, 2013
    Publication date: March 5, 2015
    Applicant: KANEKA CORPORATION
    Inventors: Ken Uekita, Tadashi Moroshima